News
Pfizer, Flynn accused of charging the NHS ‘unfairly high prices’ for anti-epilepsy drug
Pfizer and Flynn have been accused of breaking competition law by overcharging the NHS for ‘vital’ anti-epilepsy drugs, according to provisional findings from the UK Competition and Markets Authority (CMA).